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Introduction
Up to 80% of children with Juvenile Systemic Lupus
Erythematosus (JSLE) develop lupus nephritis (LN) (1),
with the 5-year renal survival rate varying between 44-94%
(2-4). Conventional markers of JSLE disease activity fail to
adequately predict impending LN flares (5), with signifi-
cant renal involvement (class III, IV or V LN) known to
occur with low level proteinuria (6). Cross-sectional adult
SLE studies have shown urinary vascular cell adhesion
molecule-1 (VCAM-1) to be significantly higher in active
LN than inactive LN or healthy controls, correlating with
traditional markers of LN disease activity (7, 8).
Objectives
To investigate the role of VCAM-1 as a urinary biomarker
in JSLE.
Methods
Urinary VCAM-1 concentrations were measured by
ELISA (R&D Systems Ltd). The assay demonstrated
108-122% linearity of dilution, and 90-106% recovery
using spike and retrieval techniques. Samples were diluted
1 in 80, and re-run at different dilutions where necessary.
JSLE patients were classified as ‘JSLE active renal’ or ‘JSLE
non-active renal’ based on the renal domain of the British
Isles Lupus Assessment Group score (BILAG) (rBILAG A/
B vs. D/E). Healthy children (HC), attending for non-
inflammatory surgery were recruited as controls.
Demographic, clinical and biomarker data were not
normally distributed, and expressed as median values
and interquartile ranges (IQR). Mann-Whitney U test
was used when comparing between groups, and
correlations utilized the Spearman rank test.
Results
Sixty-seven patients participated in the study (50 JSLE
patients and 17 healthy controls). JSLE patients had a
median age of 16.5 years (range 10.07-21.91), and 36/50
(72%) were female. All JSLE patients had a median of 5
ACR classification criteria (IQR 4-7), with a median length
of disease of 4.66 years (IQR 3.2-7.5). 23 (46%) JSLE
patients were classed as JSLE active renal disease and 27
(54%) were JSLE non-active renal. Eleven (22%) JSLE
patients had previously undergone a renal biopsy: Class IV
LN (n=3), Class III (n=6) and Class II (n=2). The healthy
controls had a median age of 12 years (range 4.0-16.0),
with 5 being female (29%).
Urinary VCAM-1 levels were significantly higher in JSLE
active renal patients (16.65 ng/mgCr [IQR 2.58-51.78]),
versus non-active renal patients (2.3ng/mgCr [IQR 0.61-
10.01], p=0.002) and HC’s (2.4ng/mgCr [0.54-4.50],
p=0.003). A statistically significant correlation was seen
between VCAM-1 levels, C3 (r= -0.38, p=0.009) and
urinary albumin-to-creatinine (UAUC) ratio (r=0.49,
p=0.001).
Conclusion
We have shown for the first time in children, that urinary
VCAM-1 is able to identify patients with active renal
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